CHAPEL HILL Cessation Therapeutics, a biotechnology company that focuses on developing treatments for substance abuse, has received a new grant from the National Institute on Drug Abuse (NIDA) to support fentanyl overdose treatment. The grant will be a multi-year award and is expected to total $14.8 million for Cessation and partner McLean Hospital, a
OVERLAND PARK, Kan. (BUSINESS WIRE) Aug 2, 2023 Dr. Vince Clinical Research (DVCR), a full-service CRO specializing in Phase I-II clinical trials, announced today the first subject was screened …